Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
帕拉丁公佈在 2024 年美國白內障和屈光手術學會 (ASCRS) 上公佈的 3 期 PL9643 MELODY-1 乾眼病 (DED) 臨床數據結果
Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS).
Palatin Technologies, Inc.（紐約證券交易所代碼：PTN）是一家基於調節黑色皮質素受體系統活性的分子開發同類首創藥物的生物製藥公司。該公司今天宣佈在美國白內障和屈光外科學會（ASA）公佈了其評估PL9643 與載體治療乾眼病（DED）的3期 PL9643 MELODY-1 關鍵臨床試驗的主要結果 CRS）。